CYTODYN INC. DL -,01 WKN: A0YHA5 ISIN: US23283M1018 Kürzel: 296 Forum: Aktien Thema: Hauptdiskussion

Bü.ffel

Wie eine Horde ***, 😅

Danke für den Tipp Schorsch! Dauert halt mal paar Wochen/Monate bei mir,bis es durchsickert.🤦 EK wäre im Winter etwas besser gewesen...

Wat mut dat mut! 🙄😅😂

🤦‍♂️

Wie immer alle hier dabei 😅🤷🏼‍♂️🤣

👍🙋‍♂️

🙋‍♂️

https://www.cytodyn.com/newsroom/press-releases/detail/371/cytodyn-to-deliver-presentation-at-biotech-showcase

👀

CytoDyn Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative Breast Cancer Trials  Download as PDFDecember 23, 2019 6:00am EST Objective clinical responses in these two patients treated with leronlimab (PRO 140) lead to plans for imminent filing of a Breakthrough Therapy Designation Application while trial enrollment efforts continue at much higher pace https://www.cytodyn.com/newsroom/press-releases/detail/370/cytodyn-reports-early-but-strong-positive-clinical

CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV  December 17, 2019 4:36pm EST In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone payments of up to $87.5 million, as well as a royalty of 50 percent on net sales. Vyera will also make an investment in CytoDyn of $4 million in the form of registered CytoDyn common stock CytoDyn will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications https://www.cytodyn.com/newsroom/press-releases/detail/369/cytodyn-signs-definitive-agreements-with-vyera

CytoDyn Reports Strong Positive Preclinical Data to Demonstrate Potential of Leronlimab in Treating Nonalcoholic Fatty Liver Disease (NAFLD) in Humanized Mouse Model https://www.cytodyn.com/newsroom/press-releases/detail/366/cytodyn-reports-strong-positive-preclinical-data-to

CytoDyn's Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers https://www.cytodyn.com/newsroom/press-releases/detail/365/cytodyns-lead-product-candidate-leronlimab-pro-140

Super Ergebnisse für Leronlimab und Fast track designation. https://www.google.com/amp/s/www.proactiveinvestors.com/companies/amp/news/906857

https://www.google.com/amp/s/seekingalpha.com/amp/article/4299047-cytodyn-less